11 Pharmaceuticals Stocks to Sell Now

11 Pharmaceuticals Stocks to Sell Now

This week, the ratings of 11 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Novartis AG Sponsored ADR (NVS) earns a F this week, moving down from last week’s grade of D. Novartis AG Sponsored ADR manufactures pharmaceutical and consumer healthcare products. For more information, get Portfolio Grader’s complete analysis of NVS stock.

This week, ANI Pharmaceuticals, Inc.’s (ANIP) rating worsens to a D from the company’s C rating a week ago. ANI Pharmaceuticals, Inc. develops, manufactures, and markets prescription and over-the-counter pharmaceuticals. The company also gets F’s in operating margin growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ANIP stock.

Dr. Reddy’s Laboratories Ltd. Sponsored ADR (RDY) declines this week from a C to a D. Dr. Reddy’s Laboratories Ltd. Sponsored ADR is a global company that produces and markets active pharmaceutical ingredients, intermediates, finished dosage forms, and biologic products. The company also gets F’s in sales growth and earnings growth. For more information, get Portfolio Grader’s complete analysis of RDY stock.

This is a rough week for Dipexium Pharmaceuticals, Inc. (DPRX). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DPRX stock.

This week, Zogenix, Inc. (ZGNX) drops from a D to a F rating. Zogenix, Inc. is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The company also gets F’s in operating margin growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZGNX stock.

Juniper Pharmaceuticals, Inc. (JNP) slips from a C to a D this week. The company also gets F’s in operating margin growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of JNP stock.

Slipping from a C to a D rating, Agile Therapeutics, Inc. (AGRX) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGRX stock.

KemPharm, Inc. (KMPH) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings revisions and free cash flow. For more information, get Portfolio Grader’s complete analysis of KMPH stock.

Alcobra Ltd. (ADHD) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADHD stock.

Lipocine, Inc.’s (LPCN) rating weakens this week, dropping to a F versus last week’s D. Lipocine, Inc. is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of LPCN stock.

EyeGate Pharmaceuticals, Inc. (EYEG) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EYEG stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/07/11-pharmaceuticals-stocks-to-sell-now-2/.

©2019 InvestorPlace Media, LLC